Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

NovaBay Pharmaceuticals (NBY) EBITDA (2016 - 2025)

Historic EBITDA for NovaBay Pharmaceuticals (NBY) over the last 17 years, with Q3 2025 value amounting to -$1.3 million.

  • NovaBay Pharmaceuticals' EBITDA rose 2624.78% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 million, marking a year-over-year increase of 3161.29%. This contributed to the annual value of -$5.8 million for FY2024, which is 4234.52% down from last year.
  • Latest data reveals that NovaBay Pharmaceuticals reported EBITDA of -$1.3 million as of Q3 2025, which was up 2624.78% from -$228000.0 recorded in Q4 2024.
  • NovaBay Pharmaceuticals' 5-year EBITDA high stood at -$228000.0 for Q4 2024, and its period low was -$9.4 million during Q4 2022.
  • Its 5-year average for EBITDA is -$2.0 million, with a median of -$1.5 million in 2021.
  • In the last 5 years, NovaBay Pharmaceuticals' EBITDA crashed by 19511.58% in 2022 and then soared by 8930.62% in 2023.
  • NovaBay Pharmaceuticals' EBITDA (Quarter) stood at -$3.2 million in 2021, then tumbled by 195.12% to -$9.4 million in 2022, then skyrocketed by 89.31% to -$1.0 million in 2023, then soared by 77.38% to -$228000.0 in 2024, then plummeted by 450.88% to -$1.3 million in 2025.
  • Its EBITDA stands at -$1.3 million for Q3 2025, versus -$228000.0 for Q4 2024 and -$1.7 million for Q3 2024.